Evaluating Sustainable Competitive Advantage
Baruch Lev
DOI: https://doi.org/10.1111/jacf.12234
2017-06-01
Journal of Applied Corporate Finance
Abstract:The author argues that, for companies to play a significant role in addressing environmental or social problems, they must first achieve sustained competitive advantage in the marketplace. And thus the source of a company's competitive advantage—and its ability to maintain that advantage over time—should be matters of great interest and concern for sustainability advocates as well as more traditional corporate investors and directors. But identifying and assessing the durability of corporate competitive advantage are difficult tasks, in part because conventional accounting‐based information like reported sales and GAAP earnings often fails to provide a timely ref lection of fundamental changes in the competitive position of enterprises. Competitive advantage is created and sustained by companies that develop and make effective use of “strategic” valuecreating assets—assets that tend to be intangible, rare, and hard for others to replicate. Using examples such as the R&D pipelines of big pharma companies, and the customer franchises of producers of subscription‐based products and services—and the underlying corporate capabilities responsible for generating such pipelines and franchises—the author emphasizes that the value of such corporate capabilities and assets does not show up on corporate balance sheets or income statements—or not at least without a significant lag. To help overcome this limitation of financial statements, the author recommends that corporate managements view their quarterly earnings conference calls with analysts and investors, as well as the Management Discussion and Analysis (MD&A) section of the annual financial report, as opportunities to provide more information about their strategic assets. Such information should be designed to help investors understand the firm's competitive strengths (and vulnerabilities) by aiming to provide the following: an inventory of the company's strategic assets—for example, in the case of a biotech or pharma company, a detailed account and estimates of the projected value of its current product pipeline; a statement of the amounts of ongoing corporate investment in strategic assets, as reflected in R&D spending, or customer acquisition costs, or purchases of exploration rights by oil and gas companies; a description of the company's efforts to protect the value of its strategic assets from possible infringement and imitation by competitors, from the disruption of such assets by innovation, or from the threat of new regulation; and a description of management's plan to use its strategic assets to create economic value.